Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Allakos Inc chart...

About the Company

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

CEO

Robert Alexander

Exchange

NASDAQ

Website

http://www.allakos.com/

$M

Total Revenue

124

Employees

$111M

Market Capitalization

-0.64

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALLK News

Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks

2mon ago, source: Zacks.com on MSN

Allakos Inc. (ALLK) has been beaten down lately with too much selling pressure. While the stock has lost 61.4% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14d ago, source: Stockhouse

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, ...

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

1mon ago, source: Business Insider

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

13d ago, source:

Net Loss: Allakos Inc ( NASDAQ:ALLK) reported a net loss of $62.6 million in Q4 2023, widening from $43.0 million in Q4 2022. R&D Expenses: R&D expenses rose to $53.8 million in Q4 2023, up from $35.4 ...

Allakos Inc.

2mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Allakos Announces a Restructuring to Focus on Development of AK006

28d ago, source: ADVFN

Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to ...

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

25d ago, source: ADVFN

Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14d ago, source: Business Insider

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory ...

Allakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

1mon ago, source: Finanznachrichten

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

15d ago, source: Yahoo Finance

ALLAKOS INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands) December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 66,440 $ 87,217 Investments 104,354 192,569 ...

Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

13d ago, source:

Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...